Product
GFH018
3 clinical trials
3 indications
Indication
Advanced Solid TumorIndication
NSCLCIndication
Stage IIIClinical trial
A Phase I Study With Single/Multiple Dose Administered to Explore the Safety/Tolerability and Pharmacokinetics of GFH018 in the Treatment of Patients With Advanced Solid TumorsStatus: Completed, Estimated PCD: 2022-08-11
Clinical trial
A Multi-center, Single-arm, and Open-label Phase Ib/II Study Exploring the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH018 in Combination With Toripalimab in the Treatment of Patients With Advanced Solid TumorsStatus: Completed, Estimated PCD: 2023-12-31
Clinical trial
A Phase 2 Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy for Patients With Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC)Status: Active (not recruiting), Estimated PCD: 2024-10-01